Acetylcysteine Market Size & Growth Analysis to 2030

The global acetylcysteine market size is anticipated to register a significant CAGR of 4.7% during the forecast period from 2021 to 2027 and estimated to reach USD 772 million by 2027. As per the latest research citings presented by the World Health Organization (WHO), it is anticipated that chronic obstructive pulmonary disease will be the 3^rd largest cause of death throughout the globe by 2030. The rising prevalence of acetaminophen overdose throughout the globe will further bolster the market growth.

Acetylcysteine is basically a derivative of the cysteine molecule with an acetyl group attached to its amino acid. N-acetyl cysteine is the prodrug of cysteine which is absorbed via the intestines and is vital in replenishing the glutathione reserves of the liver. It is enlisted in the World Health Organization (WHO) list of essential medicines.

Market Drivers:

Medical Applications: Acetylcysteine is widely used in the medical field for its therapeutic properties. It is primarily utilized as a mucolytic agent to thin and loosen mucus in the airways, making it easier to cough up. Acetylcysteine is prescribed for respiratory conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and bronchiectasis. The medical applications of acetylcysteine drive its demand in the market.

Treatment of Acetaminophen Overdose: Acetylcysteine is considered the standard treatment for acetaminophen (paracetamol) overdose, which can cause liver damage or failure. Acetylcysteine works by replenishing depleted glutathione stores in the liver, a vital antioxidant that helps protect liver cells. The prevalence of acetaminophen overdose cases contributes to the demand for acetylcysteine in the market.

Increasing Incidence of Respiratory Diseases: Respiratory diseases, including chronic bronchitis, asthma, and cystic fibrosis, continue to be a significant global health concern. The rising prevalence of these respiratory conditions drives the demand for medications such as acetylcysteine that can help manage symptoms and improve respiratory health. The increasing incidence of respiratory diseases fuels the growth of the acetylcysteine market.

Growing Awareness of Mucolytic Therapies: There is a growing awareness among healthcare professionals and patients about the benefits of mucolytic therapies in managing respiratory conditions. Mucolytics like acetylcysteine help improve lung function and reduce symptoms such as cough and sputum production. The increased awareness and understanding of the effectiveness of mucolytic therapies contribute to the demand for acetylcysteine.

Research and Development Activities: Ongoing research and development activities focused on exploring new applications and formulations of acetylcysteine drive innovation in the market. Researchers are investigating its potential use in areas such as neurodegenerative diseases, liver diseases, and as an antioxidant supplement. The continuous exploration of new therapeutic avenues expands the potential market opportunities for acetylcysteine.

Favorable Regulatory Environment: The regulatory environment plays a crucial role in the market growth of pharmaceutical products. Acetylcysteine has been approved by regulatory authorities in many countries for various medical applications, including respiratory disorders and acetaminophen overdose. The availability of regulatory approvals and guidelines simplifies the market entry process and promotes the use of acetylcysteine in healthcare settings.

Global Aging Population: The global aging population is a significant factor driving the demand for medications and treatments. Respiratory diseases and acetaminophen overdose can affect individuals of all age groups, but they may be more prevalent in older adults. As the global population continues to age, the demand for acetylcysteine as a therapeutic agent for respiratory conditions and acetaminophen overdose is expected to rise.

Pharmaceutical Industry Growth: The overall growth of the pharmaceutical industry has a positive impact on the acetylcysteine market. Pharmaceutical companies are investing in the development and production of acetylcysteine formulations to meet the increasing demand. The expansion of the pharmaceutical industry, coupled with the growing focus on respiratory health and overdose management, drives the market for acetylcysteine.

Market Outlook:

Market Insights:

Acetaminophen overdose in presently representing the largest market share in the treatment segment for the acetylcysteine market. The major factor responsible for its market growth is the constant rise in the patients suffering with fever associated with the infectious disease worldwide. Acetaminophen overdose is associated with non-compliance to the doctor’s prescription and in few cases gross negligence with the drug posology pertaining to acetaminophen. Its primary objective is to maintain and replenish the glutathione reserves of the liver and promote the non-toxic metabolism of acetaminophen. Chronic obstructive pulmonary disease (COPD) is a collective term used for the disease of the lower respiratory tract such as chronic bronchitis and emphysema. The clinical manifestation associated with COPD is shortness in breath due to excess secretion of mucus. Acetylcysteine inhalation is beneficial in reducing the adhesiveness and viscosity of the mucus and promotes its expulsion from the lower respiratory tract.

To know more about the study, request sample papers

Hospitals and clinics are leading the end-user segment for the acetylcysteine market. Patients suffering from chronic bronchitis and emphysema need to be immediately admitted to the intensive care unit to stabilize their condition. Intravenous or inhalation dose of acetylcysteine needs to be started immediately as the treatment regimen. Ambulatory surgical centers have gained prominence in the developed regions owing to its ability to treat acetaminophen overdose in patients residing in remote locations.

The acetylcysteine market research report presents the analysis of each segment from 2018 to 2027 considering 2020 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2021 to 2027.

Historical & Forecast Period

• 2018-19 – Historical Year
• 2020 – Base Year
• 2021-2027 – Forecast Period

Market Segmentation:

By Treatment:

• Acetaminophen Overdose
• Chronic Pulmonary Obstructive Disease (COPD)
• Dietary Supplement

By End-User:

• Hospital and Clinics
• Ambulatory Surgical Centers
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Geographic Coverage:

North America currently dominating the geography segment for the acetylcysteine market. As per the latest research citings brought forward by the Center for Disease Control and Prevention (CDC) the death rate of chronic pulmonary obstructive disease in the United States is approximately 44.3 per 100,000 people each year. Furthermore, the presence of key players such as Fresenius Kabi USA, LLC, Arbor Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Sandoz, Inc. etc further propels the market growth in the region. Europe is placed in the 2^nd position in the regional segment on account of the favorable reimbursement scenario for acetylcysteine used for the treatment of acute liver failure in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment in the acetylcysteine market. The rising prevalence of acetaminophen overdose on account of noncompliance to physician’s prescription and flourishing generic drugs market together with determining the acetylcysteine market growth in the region.

Market Competition Assessment:

Some of the major players operating in the global acetylcysteine market are Fresenius Kabi USA, LLC, Arbor Pharmaceuticals LLC, Zambon Group, Sandoz, Inc., and Menarini Group. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Key Companies:

• Fresenius Kabi USA, LLC.
• Arbor Pharmaceuticals LLC
• Zambon Group
• Sandoz, Inc.
• Menarini Group
• Teva Pharmaceutical Industries Ltd.
• IBSA Farmaceutici
• Sanofi S.A.
• Nippon Rika Co., Ltd.
• Cipla Limited

Key Questions Answered by Acetylcysteine Market Report:

• Global acetylcysteine market forecasts from 2021-2027
• Regional acetylcysteine market forecasts from 2021-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
• Country-level forecasts from 2021-2027 covering 15 major countries from the aforementioned regions
• Acetylcysteine submarket forecasts from 2021-2027 covering the market by treatment, by end-user, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis pertaining to the acetylcysteine market
• Analysis of the key factors driving and restraining the growth of the global, regional, and country-level acetylcysteine markets from 2021-2027
• Competitive Landscape and market positioning of top 10 players operating in the acetylcysteine market